Therapy

This AlzheimerVideoNews.com World Alzheimers Day 2008 Special Report discusses the significant progress which occurred in the field of Alzheimer clinical research in 2008, including a discussion regarding the latest promising therapeutics which address new therapeutic targets. These new agents, which were both the subject of presentations at ICAD 2008, the world’s leading forum on dementia research, and scientific publications in 2008, include Rember®, Dimebon®, and etanercept. This broadcast constitutes the debut of AlzheimerVideoNews.com, a site devoted to a critical discussion of the most important news in Alzheimer research. AlzheimerVideoNews.com Copyright 2010 INR®, all rights reserved.

Duration : 0:6:46

Read the rest of this entry »

The Baker lab is studying the properties of perfluorocarbon-based nanoscale emulsions. These emulsions are used as platforms for the delivery of therapeutic and imaging agents to cancerous cells. This video shows the formation of such an emulsion from coarse-grained models of perfluorocarbona dn lipid. This work is performed in collaboration with the Schlesinger, Wickline, and Lanza labs.

Duration : 0:0:50

Read the rest of this entry »

Lysergic acid diethylamide, abbreviated LSD or LSD-25, also known as lysergide and colloquially as acid, is a semisynthetic psychedelic drug of the ergoline and tryptamine families. LSD is non-addictive, non-toxic, and is well known for its psychological effects which can include altered thinking processes, closed and open eye visuals, synaesthesia, a sense of time distortion, ego death and spiritual experiences, as well as for its key role in 1960s counterculture. It is used mainly by psychonauts as an entheogen, recreational drug and as an agent in psychedelic therapy.

LSD was first synthesized by Albert Hofmann in 1938 from ergot, a grain fungus that typically grows on rye. The short form LSD comes from its early code name LSD-25, which is an abbreviation for the German “Lysergsäure-diethylamid” followed by a sequential number. LSD is sensitive to oxygen, ultraviolet light, and chlorine, especially in solution, though its potency may last for years if it is stored away from light and moisture at low temperature. In pure form it is a colorless, odorless, and mildly bitter solid. LSD is typically delivered orally, usually on a substrate such as absorbent blotter paper, a sugar cube, or gelatin. In its liquid form, it can also be administered by intramuscular or intravenous injection. LSD is very potent, with 2030 µg (micrograms) being the threshold dose.

Introduced by Sandoz Laboratories, with trade-name Delysid, as a drug with various psychiatric uses in 1947, LSD quickly became a therapeutic agent that appeared to show great promise. However, the emerging recreational use of the drug by youth culture in the Western world during the 1960s led to a political firestorm that resulted in its prohibition. A number of organizations—including the Beckley Foundation, MAPS, Heffter Research Institute and the Albert Hofmann Foundation—exist to fund, encourage and coordinate research into its medicinal uses.

LSD was first synthesized on November 16, 1938 by Swiss chemist Dr. Albert Hofmann at the Sandoz Laboratories in Basel, Switzerland as part of a large research program searching for medically useful ergot alkaloid derivatives. LSD’s psychedelic properties were discovered 5 years later when Hofmann accidentally ingested an unknown quantity of the chemical. The first intentional ingestion of LSD occurred on April 19, 1943, when Dr. Hofmann ingested 250 µg of LSD. He hypothesized this would be a threshold dose based on the dosages of other ergot alkaloids. Hofmann found the effects to be much stronger than he anticipated. Sandoz Laboratories introduced LSD as a psychiatric drug in 1947.

Beginning in the 1950s the US Central Intelligence Agency began a research program code named Project MKULTRA. Experiments included administering LSD to CIA employees, military personnel, doctors, other government agents, prostitutes, mentally ill patients, and members of the general public in order to study their reactions, usually without the subject’s knowledge. The project was revealed in the US congressional Rockefeller Commission report in 1975.

In 1963 the Sandoz patents expired on LSD. Also in 1963, the US Food and Drug Administration classified LSD as an Investigational New Drug, which meant new restrictions on medical and scientific use. Several figures, including Aldous Huxley, Timothy Leary, and Al Hubbard, began to advocate the use of LSD. LSD became central to the counterculture of the 1960s. On October 24, 1968, possession of LSD was made illegal in the United States. The last FDA approved human study with LSD, for use in dying cancer patients, ended in 1980. Legally approved and regulated psychiatric use of LSD continued in Switzerland until 1993. Today, medical research is resuming around the world.

Duration : 0:9:59

Read the rest of this entry »

Acute Gastritis. The causes, natural history, and therapeutic implications of gastropathy differ from gastritis:
Gastropathy is usually caused by irritants such as drugs (eg, nonsteroidal antiinflammatory agents and alcohol), bile reflux, hypovolemia, and chronic congestion.
Gastritis is usually due to infectious agents (such as Helicobacter pylori) and autoimmune and hypersensitivity reactions. Acute gastritis may produce no symptoms but can be associated with short-lived dyspepsia, lack of appetite, nausea or vomiting. It can occasionally be severe enough to cause gastrointestinal bleeding with melena or hematemesis (see above). The most common cause is ingestion of aspirin or other non-steroidal anti-imflammatory drugs (NSAIDs). It can also occur during the early stages of infection with the bacteria,
Helicobacter pylori “HP.” Most cases resolve by themselves, but endoscopy and biopsy may be required to exclude other conditions such as peptic ulcer disease or cancer. At endoscopy the inner lining of the stomach (mucosa) may appear swollen, reddened and inflamed. There may be small, shallow erosions (breaks in the surface lining) or even tiny areas of bleeding from the mucosa.

Duration : 0:0:20

Read the rest of this entry »

The New World Order wants us death. Don’t believe me? Just google “Eugenics” “agenda 21″ “chemtrails”….
This short video shot in Golden Valley Mohave County Arizona is just an example of Chemical spray in the sky…. these are not civilian jets. They do not follow a regular path or timing… we have weeks without a trace of any airplane then at specific time they appear all together.
Please also read this bill pass by Congress, especially the exceptions…
U.S. CODE TITLE 50, SECTION 1520(a) S 1520. Repealed. Pub Law. 105-85, Div. A, Title X, S 1078(g), Nov. 18, 1997, 111 Stat. 1916S 1520a. Restriction on the use of human subjects for testing of chemical or biological agents

(a) Prohibited activities The Secretary of Defense may not conduct (directly or by contract)- (1) any test or experiment involving the use of a chemical agent or biological agent on a civilian population; or (2) any other testing of a chemical agent or biological agent on human subjects.

(b) Exceptions Subject to subsections (c), (d), and (e) of this section, the prohibition in subsection (a) of this section does not apply to a test or experiment carried out for any of the following purposes: (1) Any peaceful purpose that is related to a medical, therapeutic, pharmaceutical, agricultural, industrial, or research activity. (2) Any purpose that is directly related to protection against toxic chemicals or biological weapons and agents. (3) Any law enforcement purpose, including any purpose related to riot control.

Duration : 0:7:5

Read the rest of this entry »

The UNM College of Pharmacy is building on its storied radiopharmacy program, as it works to develop a new generation of radiopharmaceuticals.

Duration : 0:3:11

Read the rest of this entry »

Welcome to The Daily Stock Report…brought to you by QualityStocks.Net, performance tracked daily.

I’m Cathy Rankin and for Friday June 29th we’re bringing you the latest news from around the markets as well as the top movers to look out for today…

(HEADLINE NEWS)

Let’s get into some of the top movers and shakers on the Quality Stocks watch list specifically what was going on last week…

Today’s report is brought to you today by Cord Blood America, Inc., (CBAI.OB)

Cord Blood America, Inc., (CBAI.OB) through its wholly owned subsidiary, Cord Partners, Inc., engages in the collection, testing, processing, and preservation of umbilical cord blood in the United States. This blood enables families to preserve cord blood at the birth of a child for use in future stem cell therapy, which uses live cells as therapeutic agents to treat disease.

nCoat, Inc. (NCOA.OB) announced that its subsidiary, High Performance Coatings, Inc. has entered a collaborative agreement with Universal Technical Institute, to train automotive engineers on the performance and use of coatings. The tests could show the benefit a high performance coating can bring to exhaust system designs in the schools, which study state-of-the-art nano-coating and micron particulate coating technology.

nCoat, Inc. is an emerging nanotechnology company with new nano-formulated and traditional coatings that make it an international leader in the development and marketing of coatings applied to metal, ceramics, fabric, and other materials.

Wi-Fi TV Inc. (WTVI.PK) announced Thursday that its URL will take new iPhone® users directly to Wi-Fi TV Inc.’s page of live content optimized for the iPhone®. The link will tie-in with the launch of a 24/7 multiplex style movie marathon which will be presented, along with the live TV stations accessible over the iPhone®.

Wi-Fi TV Inc. provides a new generation TV delivery platform that has a geographic sphere that will out-distance any traditional cable or over-the-air TV broadcaster. The Wi-Fi TV website is the only place on the Internet where you can watch hundreds of TV stations and chat with others watching the same program.

Sweet Success Enterprises (SWTS.OB) shares were boosted on yesterday’s announcement that all seven (7) of the Sweet Success ready-to-drink beverages will be available for sale on Samsclub.com beginning July 1, 2007.
Amazon.com, announced it has received its latest shipment of all products and should have them available in their system shortly.

Sweet Success Enterprises, Inc. engages in the production, distribution, and marketing of ready-to-drink functional health beverages.

Pacific Biometrics, Inc. (PBME.OB) announced Wednesday the company has been awarded a contract worth an estimated $610,000 with a top multinational pharmaceutical company. The contact is for the study of a biological treatment for rheumatoid arthritis (RA), which will provide essential laboratory data for a pivotal, global Phase III program.

And that’s our newsmakers, Stay tuned right here to Quality Stocks Daily for the latest news from small cap to large cap, and everything in by QualityStocks.Net, where performance is tracked daily.

Thank you for tuning in, I’m Cathy Rankin, Have a great day and we’ll see you tomorrow, right here on the daily report.

Please see Disclaimer on site: http://Disclaimer.QualityStocks.net

Duration : 0:4:20

Read the rest of this entry »

Go behind the scenes at IMBCR and see our multi-million dollar laboratory, where many of the novel therapeutic agents for multiple myeloma have been created. For more information about our research and how we’re helping patients world-wide, please visit www.imbcr.org

Duration : 0:1:11

Read the rest of this entry »

The director of the Center for Translational Research in Neurodegenerative Diseases at the University of Florida received the MetLife Foundation Awards for Medical Research in Alzheimer’s Disease during a scientific briefing and luncheon today (Thursday, Feb. 25) in Washington, D.C.

Todd Golde, M.D., a professor of neuroscience in the College of Medicine, studies amyloid beta protein, a substance believed to contribute to the accumulation of “brain plaque” in Alzheimer’s patients.

Golde helped explain the molecular interplay between amyloid beta protein and a class of therapeutic agents known as gamma-secretase modulators, or GSMs, now being tested in patients with Alzheimer’s disease.

Duration : 0:2:19

Read the rest of this entry »

In this 1955 film, a CIA-funded study examines medical experiments to determine the efficacy of LSD-25 and MER 17 (Frenquel) on treating psychosis.

Lysergic acid diethylamide (LSD-25, LSD), formerly lysergide, commonly known as acid, is a semisynthetic psychedelic drug of the ergoline and tryptamine families. LSD is non-addictive, non-toxic, and is well known for its psychological effects which can include altered thinking processes, closed and open eye visuals, synaesthesia, a sense of time distortion, ego death and spiritual experiences, as well as for its key role in 1960s counterculture. It is used mainly by psychonauts as an entheogen and in psychedelic therapy.

LSD was first synthesized by Albert Hofmann in 1938 from ergot, a grain fungus that typically grows on rye. The short form LSD comes from its early code name LSD-25, which is an abbreviation for the German “Lysergsäure-diethylamid” followed by a sequential number. LSD is sensitive to oxygen, ultraviolet light, and chlorine, especially in solution, though its potency may last for years if it is stored away from light and moisture at low temperature. In pure form it is a colourless, odourless, and mildly bitter solid. LSD is typically delivered orally, usually on a substrate such as absorbent blotter paper, a sugar cube, or gelatin. In its liquid form, it can also be administered by intramuscular or intravenous injection. LSD is very potent, with 2030 µg (micrograms) being the threshold dose.

Introduced by Sandoz Laboratories, with trade-name Delysid, as a drug with various psychiatric uses in 1947, LSD quickly became a therapeutic agent that appeared to show great promise. However, the emerging recreational use of the drug by youth culture in the Western world during the 1960s led to a political firestorm that resulted in its prohibition. A number of organizations—including the Beckley Foundation, MAPS, Heffter Research Institute and the Albert Hofmann Foundation—exist to fund, encourage and coordinate research into its medicinal uses.

LSD was first synthesized on November 16, 1938 by Swiss chemist Dr. Albert Hofmann at the Sandoz Laboratories in Basel, Switzerland as part of a large research program searching for medically useful ergot alkaloid derivatives. LSD’s psychedelic properties were discovered 5 years later when Hofmann accidentally ingested an unknown quantity of the chemical. The first intentional ingestion of LSD occurred on April 19, 1943, when Dr. Hofmann ingested 250 µg of LSD. He hypothesized this would be a threshold dose based on the dosages of other ergot alkaloids. Hofmann found the effects to be much stronger than he anticipated. Sandoz Laboratories introduced LSD as a psychiatric drug in 1947.

Beginning in the 1950s the US Central Intelligence Agency began a research program code named Project MKULTRA. Experiments included administering LSD to CIA employees, military personnel, doctors, other government agents, prostitutes, mentally ill patients, and members of the general public in order to study their reactions, usually without the subject’s knowledge. The project was revealed in the US congressional Rockefeller Commission report in 1975.

In 1963 the Sandoz patents expired on LSD. Also in 1963, the US Food and Drug Administration classified LSD as an Investigational New Drug, which meant new restrictions on medical and scientific use. Several figures, including Aldous Huxley, Timothy Leary, and Al Hubbard, began to advocate the use of LSD. LSD became central to the counterculture of the 1960s. On October 24, 1968, possession of LSD was made illegal in the United States. The last FDA approved human study with LSD, for use in dying cancer patients, ended in 1980. Legally approved and regulated psychiatric use of LSD continued in Switzerland until 1993. Today, medical research is resuming around the world.

Duration : 0:10:59

Read the rest of this entry »